Pearson
This article was originally published in The Tan Sheet
Executive Summary
FDA postpones ruling on omega-3 fatty acids/coronary heart disease health claim until Oct. 31 and antioxidants/cancer claim until Nov. 30, agency informs Emord & Associates Oct. 24. Although mainly due to lack of resources and staffing, the delay of the omega-3 review also reflects the "new and complex issues raised by the use of a qualifier with a health claim," FDA says. For the antioxidants/cancer claim, the agency says it needs more time because the issue involves relationships between more than one nutrient and several types of cancer. FDA has acted on two Pearson claims, endorsing a qualified folic acid claim but denying the requested folic acid/NTD and fiber/colorectal cancer claims (1"The Tan Sheet" Oct. 16, pp. 3-4)